HC Wainwright Issues Pessimistic Forecast for Viridian Therapeutics (NASDAQ:VRDN) Stock Price

Viridian Therapeutics (NASDAQ:VRDN) had its target price decreased by research analysts at HC Wainwright from $34.00 to $22.00 in a note issued to investors on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s target price points to a potential upside of 14.88% from the company’s current price. HC Wainwright also issued estimates for Viridian Therapeutics’ Q1 2026 earnings at ($1.16) EPS, Q2 2026 earnings at ($1.22) EPS, Q4 2026 earnings at ($1.17) EPS and FY2026 earnings at ($4.75) EPS.

A number of other research analysts have also recently weighed in on VRDN. UBS Group began coverage on shares of Viridian Therapeutics in a report on Wednesday, January 7th. They issued a “buy” rating and a $50.00 price objective for the company. Wells Fargo & Company increased their target price on shares of Viridian Therapeutics from $26.00 to $29.00 and gave the stock an “equal weight” rating in a report on Tuesday, February 3rd. Evercore reissued an “outperform” rating and issued a $44.00 price target on shares of Viridian Therapeutics in a research report on Tuesday, January 20th. Truist Financial dropped their price target on shares of Viridian Therapeutics from $41.00 to $40.00 and set a “buy” rating for the company in a research note on Thursday, January 8th. Finally, Wall Street Zen lowered Viridian Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. Thirteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $39.21.

Viridian Therapeutics Stock Down 2.1%

NASDAQ:VRDN opened at $19.15 on Tuesday. Viridian Therapeutics has a 52 week low of $9.90 and a 52 week high of $34.29. The company has a quick ratio of 12.65, a current ratio of 12.65 and a debt-to-equity ratio of 0.08. The stock’s fifty day moving average is $28.90 and its two-hundred day moving average is $27.83. The stock has a market capitalization of $1.96 billion, a price-to-earnings ratio of -5.82 and a beta of 1.16.

Viridian Therapeutics (NASDAQ:VRDN) last announced its earnings results on Thursday, February 26th. The company reported ($1.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.18). The firm had revenue of $0.13 million for the quarter, compared to analysts’ expectations of $15.75 million. Viridian Therapeutics had a negative net margin of 483.57% and a negative return on equity of 83.25%. Research analysts anticipate that Viridian Therapeutics will post -4.03 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Vanguard Group Inc. grew its position in shares of Viridian Therapeutics by 29.6% in the 4th quarter. Vanguard Group Inc. now owns 5,612,144 shares of the company’s stock valued at $174,650,000 after buying an additional 1,280,161 shares during the last quarter. Commodore Capital LP raised its stake in Viridian Therapeutics by 35.4% during the 2nd quarter. Commodore Capital LP now owns 4,875,000 shares of the company’s stock worth $68,152,000 after acquiring an additional 1,275,000 shares in the last quarter. State Street Corp lifted its position in Viridian Therapeutics by 35.7% in the fourth quarter. State Street Corp now owns 3,466,560 shares of the company’s stock valued at $107,879,000 after acquiring an additional 912,394 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in Viridian Therapeutics by 42.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,439,414 shares of the company’s stock valued at $107,036,000 after acquiring an additional 1,021,310 shares during the last quarter. Finally, Perceptive Advisors LLC boosted its stake in Viridian Therapeutics by 108.1% in the fourth quarter. Perceptive Advisors LLC now owns 3,042,703 shares of the company’s stock valued at $94,689,000 after acquiring an additional 1,580,303 shares in the last quarter.

More Viridian Therapeutics News

Here are the key news stories impacting Viridian Therapeutics this week:

• Positive Sentiment: Company reported positive topline results from the Elegrobart Phase 3 REVEAL‑1 trial in active thyroid eye disease — the clinical readout is a fundamental positive for long‑term drug value and commercial potential. Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease
• Neutral Sentiment: HC Wainwright reiterated a Buy rating and set a $22 target while revising Q1–Q4 and FY2026 EPS estimates (small mix of raises and cuts) — shows continued analyst support but revised modeling reflects higher near‑term costs/assumptions. HC Wainwright estimate and rating note
• Neutral Sentiment: Recent intraday swings included a sharp bounce the prior session (Zacks noted a 5.6% jump on higher‑than‑average volume), highlighting that VRDN is trading on headline events and momentum as much as fundamentals. Viridian Therapeutics (VRDN) Soars 5.6%
• Negative Sentiment: Shares plunged pre‑market on headlines that followed the Phase 3 disclosure (market reaction suggests investors were disappointed by details beyond topline, or that expectations were higher), triggering heavy selling and volatility. VRDN stock plummeted 41% pre-market today
• Negative Sentiment: Multiple firms trimmed price targets (Goldman Sachs to $36, Wells Fargo to $20 with an equal‑weight, Wedbush to $37, HC Wainwright down to $22) — these cuts signal reduced near‑term upside in sell‑side models and likely contributed to downward pressure. Broker price target updates
• Negative Sentiment: Several news outlets highlighted that shares fell despite the positive topline, suggesting investor concerns about safety details, subgroup results, magnitude of benefit, or commercial assumptions — expect continued headline‑driven trading until full data and guidance are clarified. Viridian Therapeutics stock tumbles despite trial success

About Viridian Therapeutics

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.